[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Newman SL, Griffith AY, Herbst AB, Yeh IT, Kukora JS: An unusual initial manifestation of metastatic papillary thyroid carcinoma: radioiodine uptake in lymph node metastatic lesions in a patient with Graves' disease. Endocr Pract; 2002 Jul-Aug;8(4):304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual initial manifestation of metastatic papillary thyroid carcinoma: radioiodine uptake in lymph node metastatic lesions in a patient with Graves' disease.
  • OBJECTIVE: To report an unusual manifestation of metastatic papillary thyroid carcinoma with functional metastatic lesions demonstrated by radioiodine scanning and to discuss the relationship of Graves' disease and thyroid carcinoma.
  • 123I thyroid uptake scanning demonstrated lateral uptake, which directed attention to the lateral aspect of the neck and resulted in subsequent identification of previously overlooked lymphadenopathy.
  • CONCLUSION: In two previous reports of similar cases of metastatic thyroid carcinoma, imaging was done with use of a different scanning agent.
  • To our knowledge, this is the first published case report of functional metastatic lesions imaged with 123I before thyroidectomy.
  • This preoperative finding facilitated clinical management of the patient's thyroid cancer and thyrotoxicosis.
  • [MeSH-major] Carcinoma, Papillary / radionuclide imaging. Graves Disease / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Graves' Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endocr Pract. 2003 Jul-Aug;9(4):328-9 [14569975.001]
  • (PMID = 12173918.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


2. Caglar M, Naldöken S: Multiple brown tumors simulating bone metastases: a case of parathyroid adenoma coexisting with papillary carcinoma of the thyroid. Clin Nucl Med; 2000 Oct;25(10):772-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple brown tumors simulating bone metastases: a case of parathyroid adenoma coexisting with papillary carcinoma of the thyroid.
  • He had elevated parathyroid hormone levels and was referred to the nuclear medicine department, where a parathyroid adenoma was diagnosed.
  • At surgery, abnormal lymph nodes were seen, which were found to contain metastatic thyroid papillary carcinoma cells.
  • [MeSH-major] Adenoma / radionuclide imaging. Carcinoma, Papillary / pathology. Neoplasms, Multiple Primary. Parathyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11043714.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


3. Sheahan P, Hafidh M, Toner M, Timon C: Unexpected findings in neck dissection for squamous cell carcinoma: incidence and implications. Head Neck; 2005 Jan;27(1):28-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected findings in neck dissection for squamous cell carcinoma: incidence and implications.
  • These pathologic findings may simulate malignant disease and/or have implications on the already complicated management of patients with head and neck cancer.
  • METHODS: We retrospectively reviewed 202 consecutive patients with a preoperative diagnosis of squamous cell carcinoma (SCC), who underwent 307 neck dissections performed by a single surgeon and examined by a single pathologist.
  • These included metastatic papillary thyroid carcinoma, leukemia, lymphoma, Warthin's tumor, and tuberculosis.
  • Two of three patients with benign-appearing thyroid tissue within lymph nodes received no further treatment, and both remained well beyond 6 years.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neck Dissection
  • [MeSH-minor] Adenolymphoma / pathology. Adenolymphoma / therapy. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cricoid Cartilage / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphatic Metastasis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Middle Aged. Retrospective Studies. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary. Thyroid Neoplasms / surgery. Thyroidectomy. Tuberculosis, Lymph Node / drug therapy. Tuberculosis, Lymph Node / pathology


Advertisement
4. Agriantonis DJ, Hall L, Wilson MA: Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer. Clin Nucl Med; 2009 Apr;34(4):247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer.
  • We present a case of papillary thyroid cancer metastatic to the liver, a relatively rare scenario.
  • SPECT/CT allowed definitive lesion characterization at the time of the patient's visit to the nuclear medicine department.
  • [MeSH-major] Iodine Radioisotopes / pharmacology. Liver Neoplasms / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Diagnostic Imaging. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiopharmaceuticals. Whole Body Imaging / methods


5. Ikeda M, Tanaka K, Sonoo H, Miyake A, Yamamoto Y, Shiiki S, Nakashima K, Kurebayashi J: [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma]. Gan To Kagaku Ryoho; 2007 Jun;34(6):933-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma].
  • We report three radioiodine-resistant patients with metastatic papillary thyroid carcinoma administered docetaxel.
  • Since no effective systemic treatment has been established for radioiodine-resistant patients with metastatic papillary thyroid carcinoma,docetaxel therapy was supposed to be a viable alternative for them.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Papillary / drug therapy. Taxoids / administration & dosage. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Iodine Radioisotopes. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565260.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / Taxoids; 15H5577CQD / docetaxel; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


6. Short SC, Suovuori A, Cook G, Vivian G, Harmer C: A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol); 2004 Dec;16(8):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.
  • AIMS: Radio-iodine is effective in treating metastatic differentiated thyroid cancers.
  • Failure of iodine uptake might be reversible using redifferentiating agents.
  • Retinoids redifferentiate a variety of cell types and increase iodine uptake in thyroid tumour cells in vitro.
  • The aim of this study was to assess whether oral isotretinoin could increase radio-iodine uptake in patients with iodine-uptake-negative metastatic thyroid cancer.
  • METHODS: Patients who had iodine-uptake-negative metastatic papillary or follicular thyroid cancers were selected from the thyroid database at The Royal Marsden Hospital and enrolled to an open-label, non-randomised phase II trial.
  • Sites of metastatic disease were assessed using computed tomography or magnetic resonance imaging, and absence of iodine uptake was confirmed using a diagnostic radio-iodine scan before study entry.
  • RESULTS: Sixteen patients were treated with isotretinoin between January 2001 and July 2002: nine with metastatic papillary thyroid cancer, five with metastatic follicular cancer and two with Hurthle cell carcinoma.
  • In one patient, radio-iodine uptake increased after retinoid administration; however, this was not large enough to permit a significant dose of iodine to be given to sites of metastatic disease.
  • CONCLUSION: Treatment with isotretinoin does not reliably increase radio-iodine uptake in patients with metastatic thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / drug therapy. Adenocarcinoma, Follicular / radiotherapy. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / radiotherapy. Iodine Radioisotopes / pharmacokinetics. Iodine Radioisotopes / therapeutic use. Isotretinoin / pharmacology. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630851.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EH28UP18IF / Isotretinoin
  •  go-up   go-down


7. Bernet VJ: Reversible renal insufficiency attributable to thyroid hormone withdrawal in a patient with type 2 diabetes mellitus. Endocr Pract; 2004 Jul-Aug;10(4):339-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible renal insufficiency attributable to thyroid hormone withdrawal in a patient with type 2 diabetes mellitus.
  • OBJECTIVE: To present a case of papillary thyroid carcinoma and the need for follow-up surveillance in a patient with type 2 diabetes mellitus who was being treated with metformin.
  • A discussion addresses the importance of monitoring renal function during thyroid hormone withdrawal for scintigraphic imaging with use of radioactive iodine.
  • RESULTS: A 60-year-old man with type 2 diabetes was diagnosed with metastatic papillary thyroid carcinoma, and renal insufficiency developed during withdrawal from thyroid hormone for surveillance 131 I whole-body scanning.
  • An increase in thyroglobulin attributable to recombinant human thyrotropin stimulation led to detection of persistent cancer, and thyroid hormone withdrawal was begun in preparation for further 131 I treatment.
  • In patients with diabetes taking metformin who have hypothyroidism for any reason including thyroid hormone withdrawal, serum Cr levels should be monitored until thyroid hormone levels normalize.
  • [MeSH-major] Adenocarcinoma, Papillary / radionuclide imaging. Renal Insufficiency / etiology. Thyroid Hormones / adverse effects. Thyroid Neoplasms / radionuclide imaging. Withholding Treatment
  • [MeSH-minor] Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / drug therapy. Diagnostic Techniques, Radioisotope. Humans. Hypoglycemic Agents / therapeutic use. Iodine Radioisotopes / therapeutic use. Male. Metformin / therapeutic use. Middle Aged. Neck Dissection. Radiopharmaceuticals / therapeutic use. Thyroid Function Tests / methods. Thyroidectomy

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • Genetic Alliance. consumer health - Diabetes mellitus type 2.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15760778.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thyroid Hormones; 9100L32L2N / Metformin
  •  go-up   go-down






Advertisement